Skip to main content
. Author manuscript; available in PMC: 2017 Nov 22.
Published in final edited form as: Nanomedicine. 2016 Aug 20;13(2):411–420. doi: 10.1016/j.nano.2016.08.006

Figure 2. Reactivity of N-FsII-nanorings with specific antibodies.

Figure 2

(A) The reactivity of N-FsII-nanorings or N-nanorings (N) with specific antibodies was evaluated by ELISA using sera collected from postfusion F (F) immunized mice (anti-F serum), N-nanorings immunized mice (anti-N serum) or naive mice (control serum), or FsII-specific monoclonal antibody (AbD Serotec). Data are mean ± SEM of triplicate to septuplicate values (two experiments). Nonlinear regression was done using Boltzmann sigmoidal equation. (B) Reactivity of N-FsII-nanorings or F with palivizumab was evaluated by ELISA. Data are mean ± SEM of triplicate to quadruplicate values. Non-linear regression was done using Boltzmann sigmoidal equation. Dissociation constants (Kd) were calculated from saturation curves obtained after baseline correction (N curve) and non-linear regression.